Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome

NCT ID: NCT01886781

Last Updated: 2014-09-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with IBS, will supplementation with a probiotic demonstrate symptomatic efficacy and will the probiotic influence gut microflora and thus improve clinical outcomes, as compared to no intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conduct a study on nutrient intakes gastrointestinal microbiota and the effect of a probiotic, Lactobacillus plantarum 299v in irritable bowel syndrome patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lactobacillus plantarum 299v

Lactobacillus plantarum 299v capsules

Group Type EXPERIMENTAL

Lactobacillus plantarum 299v

Intervention Type DRUG

two capsules of 5 X 10 \^9 c.f.u each

Run in period

Intervention Type OTHER

Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo

Wash - out period

Intervention Type OTHER

Wash - out period following treatment phase of eight weeks

Crytalline cellulose powder

Placebo capsule, filled with micro-crystalline cellulose powder

Group Type PLACEBO_COMPARATOR

Placebo comparator

Intervention Type DRUG

Micro-crystalline cellulose powder, identical taste, texture and appearance

Run in period

Intervention Type OTHER

Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo

Wash - out period

Intervention Type OTHER

Wash - out period following treatment phase of eight weeks

Run in period

Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.

Group Type NO_INTERVENTION

No interventions assigned to this group

Wash out period

Wash out period of two weeks, no treatment.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactobacillus plantarum 299v

two capsules of 5 X 10 \^9 c.f.u each

Intervention Type DRUG

Placebo comparator

Micro-crystalline cellulose powder, identical taste, texture and appearance

Intervention Type DRUG

Run in period

Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo

Intervention Type OTHER

Wash - out period

Wash - out period following treatment phase of eight weeks

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lp 299v Run in period to baseline Wash - out following treatment phase of eight weeks

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* fulfillment of the Rome II criteria for IBS,
* availability of at least one colonoscopy within the last three years,
* aged 18 or older at the time of screening,
* provision of written informed consent,
* commitment of availability throughout the 12 week study period.

Exclusion Criteria

* major abdominal surgery in the past other than other than appendectomy, caesarean section, tubal laparoscopic cholecystectomy, abdominal wall hernia repair or/and hysterectomy,
* current use of antibiotics,
* history of organic intestinal disease,
* pregnant or breastfeeding mothers,
* chronic infectious disease like HIV or tuberculosis, and
* unable to understand English or Afrikaans.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nestlè Nutrition Institute Africa

OTHER

Sponsor Role collaborator

National Research Foundation (NRF) (RSA)

UNKNOWN

Sponsor Role collaborator

University of Stellenbosch

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cheryl Stevenson

Mrs

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cheryl Stevenson, M.Sc

Role: PRINCIPAL_INVESTIGATOR

Univeristy of Stellenbosch

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Netcare Greenacres Hospital

Port Elizabeth, Eastern Cape, South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Africa

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N10-08-270

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics in Irritable Bowel Syndrome
NCT00846170 WITHDRAWN PHASE3